Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.

Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H.

J Nephrol. 2017 Feb;30(1):127-134. doi: 10.1007/s40620-016-0288-3. Epub 2016 Mar 19.

2.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.

Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.

3.

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.

Clin Exp Nephrol. 2019 Jan;23(1):112-121. doi: 10.1007/s10157-018-1610-2. Epub 2018 Jul 23.

4.

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C.

Kidney Int. 2015 May;87(5):1061-73. doi: 10.1038/ki.2014.423. Epub 2015 Feb 4.

5.

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.

J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.

6.

Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.

Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S.

Clin Exp Nephrol. 2016 Apr;20(2):265-72. doi: 10.1007/s10157-015-1142-y. Epub 2015 Jul 9.

PMID:
26156042
7.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
8.

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.

Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R.

Ther Apher Dial. 2018 Apr;22(2):178-188. doi: 10.1111/1744-9987.12641. Epub 2017 Dec 17.

PMID:
29250893
9.

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.

Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.

10.

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31.

11.

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H.

Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29.

12.

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.

Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.

PMID:
26247170
13.

Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.

Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.

Transfus Apher Sci. 2016 Dec;55(3):357-362. doi: 10.1016/j.transci.2016.09.017. Epub 2016 Sep 30.

PMID:
27742267
14.

[Use of Eculizumab in atypical hemolytic uremic syndrome after renal transplantation].

Teixeira CI, Mota RG, Afonso BG, Carneiro TV, Meira GS, Mendonça DU.

J Bras Nefrol. 2015 Jan-Mar;37(1):127-30. doi: 10.5935/0101-2800.20150018. Portuguese.

15.

First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.

Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F.

Paediatr Drugs. 2016 Dec;18(6):413-420.

PMID:
27646857
16.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

17.

Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.

Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommelé Å, Wang J, Weekers LE, Sheerin NS.

Transpl Int. 2017 Dec;30(12):1275-1283. doi: 10.1111/tri.13022. Epub 2017 Sep 8.

18.

Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.

Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O.

Pediatr Nephrol. 2015 May;30(5):783-9. doi: 10.1007/s00467-014-3003-4. Epub 2014 Nov 11.

PMID:
25384530
19.

An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.

Sengul Samanci N, Ayer M, Ergen A, Ozturk S.

Transfus Apher Sci. 2015 Jun;52(3):314-6. doi: 10.1016/j.transci.2015.01.006. Epub 2015 Jan 12.

PMID:
25634788
20.

Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.

Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M.

Am J Kidney Dis. 2014 Oct;64(4):633-7. doi: 10.1053/j.ajkd.2014.01.434. Epub 2014 Mar 19.

PMID:
24656451

Supplemental Content

Support Center